SC Engineering, Cellontech Sign 'CartiPhil' Supply Contract with Chinese Artificial Joint Specialist Company

Cellontech, a subsidiary of SC Engineering, is expanding into the joint cartilage regenerative medical market following its entry into the Chinese beauty and plastic surgery market.

Cellontech, a specialized bio company in regenerative medicine, announced on the 15th that it has signed a supply contract for the joint cartilage regenerative treatment medical device "CartiFill" with China's Just Medical Devices (Tianjin), hereinafter referred to as Just Medical.

Under this contract, Cellontech is guaranteed a minimum order quantity (MOQ) worth $21 million (approximately 29 billion KRW) from Just Medical over the next five years. If demand increases thereafter, the minimum guaranteed contract amount may be further increased through negotiation.

Founded in 1958, Just Medical is an orthopedic medical device specialist company based in Tianjin, China, with a diverse value chain covering research and development, manufacturing, distribution, and marketing of artificial joints and medical equipment. It has established a vast sales network with over 4,000 partner hospitals nationwide and more than 500 sales channels throughout China.

CartiFill is Korea’s first gel-type joint cartilage regenerative treatment medical device developed using Cellontech’s proprietary bio-collagen as the raw material. It is an implantable tissue regeneration scaffold that helps position cartilage cells and bone marrow cells during improved microfracture surgery, and it received approval from the Ministry of Food and Drug Safety in 2013. It has also been recognized as a treatment material corresponding to new medical technology announced by the Korea Health Industry Development Institute under the Ministry of Health and Welfare in 2013.

A Cellontech official stated, “It is significant that, following our earlier entry into the Chinese beauty and plastic surgery market in cooperation with Sahwan Pharmaceutical, we have now penetrated the local joint cartilage regenerative medical market by partnering with Just Medical, a leading company in China’s orthopedic field. We expect the synergy between Just Medical’s distribution network in China and the competitiveness of Cellontech’s CartiFill, combined with China’s vast market potential, to create a very strong market impact.”

In addition to CartiFill, Cellontech is strengthening its position in the domestic and international osteoarthritis markets through the intra-articular injection product "CartiZol." Recently, it has expanded its domestic sales network by consecutively signing joint marketing contracts for CartiZol with LG Chem, Kolon Pharmaceutical, and Dongkook Pharmaceutical. For overseas markets, it continues to develop sales channels by signing supply contracts with major local medical device distributors in Thailand and Vietnam, large markets within ASEAN (Association of Southeast Asian Nations).

The official added, “The technological competitiveness and marketability of Cellontech’s bio-collagen medical devices are simultaneously driving the expansion of both domestic and international markets. We will continue to accelerate efforts to secure growth momentum that will lead to mid- to long-term sales increases.”

This content was produced with the assistance of AI translation services.